Bezuclastinib mean TSS reduction deepens to -32.0 points at 48 weeks of treatment with further improvement shown across all measured symptoms99% of patients achieve >50% reduction in serum tryptase at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results